By Fineline Cube 
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) released its 2024 financial report, alongside its Q1 2025 financial performance. In 2024, the company generated RMB 360 million (USD 49.5 million) in revenues, a 294% year-on-year (YOY) increase. In the first quarter of 2025, operating revenue soared by 96% YOY to RMB 160 million (USD 22 million).
Key Developments and Sales Performance
In November 2024, the company’s EGFR inhibitor sunvozertinib and JAK1 inhibitor Gaoruizhe (golidocitinib) were included in the National Reimbursement Drug List (NRDL), driving rapid sales growth. Sunvozertinib is currently awaiting regulatory decisions in the US with priority review status.
Financial Metrics and Cost Management
While achieving significant sales growth, Dizal Pharmaceutical managed to reduce its sales expense ratio to 77% in Q1 2025, compared to 124% for the entire year of 2024. Research and development expenses have remained stable and slightly decreased over the past two years, despite the launch of two in-house developed innovative drugs.
Net Loss and Future Outlook
During the reporting period in 2024, the net loss attributable to the shareholders of the parent company was approximately RMB 850 million (USD 117 million), a 24% decrease YOY. In the first quarter of 2025, the net loss attributable to shareholders of the parent company was approximately RMB 190 million (USD 26 million), a 14% drop.-Fineline Info & Tech